- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01759472
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test
January 6, 2013 updated by: Xu Shi, Guangzhou Institute of Respiratory Disease
Effect of Montelukast on Leukotriene Sensitive Asthma Detected by LTD4 Bronchial Provocation Test
To determine whether LTD4-BPT could be an effective indicator for predicting efficacy of anti-leukotriene therapy, allowing objective proofs for the use of LTRA among asthmatics in a specific sensitive to leukotriene population of asthma.
Hypothesis :Monteluakst can better improve pre-challenge FEV1 from baseline in leukotriene-sensitive group than leukotriene-insensitive group.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Guangzhou Institute of Respiratory Disease, State Key Laboratory of Respiratory Disease
-
Contact:
- Shi Xu, doctor
- Phone Number: +8618026250151
- Email: shixu1003@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 60 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Bronchial Asthma patients
Description
Inclusion Criteria:
- Aged 15-60 years, male or female.
- Mild to moderate persistent asthma.
- Mini AQLQ score ≤6 or ACQ score ≥1.
- Giving written informed consent.
Exclusion Criteria:
- Current smoker or quitted smoking ≤12 months.
- Significant allergen exposure.
- Respiratory tract infection within 2 weeks before or during the study.
- Cardiovascular disease.
- History of malignant disease within the preceding 5 years.
- And/or concomitant pulmonary disease.
- Pregnant or breast-feed period.
- Use of leukotrienes receptor antagonist within 5 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
montelukast,vitamin C pill
leukotriene receptor antagonist:(montelukast),montelukast (10 mg, once per night),56 days vitamin C pill:100mg,once per night,56 days
|
montelukast, vitamin C pill
montelukast:10 mg, once per night,56 days vitamin C pill:100mg,once per night,56 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
whether there was improvement in pre-challenge FEV1%
Time Frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
|
The primary outcome was a qualitative measure, with the results being expressed as either yes or no ('1' or '0' in Logistic model).A higher FEV1% is more suggestive of instability of asthma control.
|
from commencement of LTRA therapy to (7±2) days and (56±5) days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
whether there was improvement in post- treatment FENO
Time Frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
|
In Logistic regression model, whether there was improvement shown in post-treatment FENO as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'.
Thus the measure was qualitative one.
FENO represented fractional exhaled nitric oxide above.
|
from commencement of LTRA therapy to (7±2) days and (56±5) days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
whether there was improvement in post- treatment PD20FEV1-MCH
Time Frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
|
In Logistic regression model, whether there was improvement shown in post-treatment PD20FEV1-MCH as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'.
Thus the measure above was qualitative.
PD20FEV1-MCh referred to as the provocative dosage causing a 20% fall in FEV1 while using methacholine as a bronchoprovocant.
|
from commencement of LTRA therapy to (7±2) days and (56±5) days
|
whether there was improvement in post- treatment AQLQ symptom score
Time Frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
|
In Logistic regression model, whether there was improvement shown in post-treatment AQLQ symptom score as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'.
Thus the measure above was qualitative.
Items with regard to asthma symptoms were extracted from the whole AQLQ score, with the total score of 84.
Higher score represented better asthma control.
|
from commencement of LTRA therapy to (7±2) days and (56±5) days
|
whether there was improvement in post- treatment ACT score
Time Frame: from commencement of LTRA therapy to (56±5) days
|
In Logistic regression model, whether there was improvement shown in post-treatment ACT score as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'.
Thus the measure above was qualitative.
The total score of ACT was 25, with 5 questions in all.
Higher score was indicative of better asthma control.
|
from commencement of LTRA therapy to (56±5) days
|
whether there was a gradual decrease in weekly use of salbutamol
Time Frame: from commencement of LTRA therapy to (56±5) days
|
In Logistic regression model, whether there was a gradual decrease in weekly use of salbutamol as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'.
Thus the measure was qualitative one.
|
from commencement of LTRA therapy to (56±5) days
|
improvement in weekly and monthly PEFR
Time Frame: from commencement of LTRA therapy to (56±5) days
|
The primary outcome was a qualitative measure, with the results being expressed as either yes or no ('1' or '0' in Logistic model).PEFR was defined as the changed rate of peak expiratory flow, which was calculated using the formula according to maximal PEF (PEFmax) and minimal PEF (PEFmin) measured by portable PEF monitor: 100%*(PEFmax-PEFmin)/[(PEFmax+PEFmin)*1/2].
A higher PEFR is more suggestive of instability of asthma control.
|
from commencement of LTRA therapy to (56±5) days
|
whether there was improvement in post- treatment PD20FEV1-LTD4
Time Frame: from commencement of LTRA therapy to (7±2) days and (56±5) days
|
In Logistic regression model, whether there was improvement shown in post-treatment PD20FEV1-LTD4 as compared with pre-treatment level was expressed as either 'yes' or 'no', with symbols of '1' or '0'.
Thus the measure above was qualitative.
PD20FEV1-LTD4 referred to as the provocative dosage causing a 20% fall in FEV1 while using Leukotriene D4 as a bronchoprovocant.
|
from commencement of LTRA therapy to (7±2) days and (56±5) days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2012
Primary Completion (Anticipated)
September 1, 2013
Study Registration Dates
First Submitted
December 28, 2012
First Submitted That Met QC Criteria
December 28, 2012
First Posted (Estimate)
January 3, 2013
Study Record Updates
Last Update Posted (Estimate)
January 8, 2013
Last Update Submitted That Met QC Criteria
January 6, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012BAI05B01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchial Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SamA Pharmaceutical Co., LtdCompleted
-
Johann Wolfgang Goethe University HospitalCompleted
-
AstraZenecaRecruitingBronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)Japan
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Poland, Germany, Ukraine, Czech Republic
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Johann Wolfgang Goethe University HospitalWithdrawnAllergy | Allergic Asthma | Intrinsic Asthma | Bronchial HyperresponsivenessGermany